Osimertinib, a specific T790M inhibitor that was fast-track approved by the US FDA in November 2015 for treatment of patients with metastatic EGFR-T790M mutation-positive NSCLC as detected by an FDA-approved test (Cobas® EGFR Mutation Test v2) after EGFR-TKI failure, achieved overall response rates (ORR) of up to 70% and progression-free survival (PFS) times of around 12 months [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.